Horizon Therapeutics plc and Massachusetts Institute of Technology (MIT) Solve Announce the Launch of the Third Annual Horizon Prize to Inspire Sustainable Solutions for Research and Care in the Rare Disease Community
Each year, the Horizon Prize poses a challenge question, asking entrepreneurs and innovators worldwide to think creatively to solve a relevant issue in the rare disease community. One winner will be awarded a total of
An estimated
- Improving the rare disease patient diagnostic journey (reducing time, cost, etc.)
- Enhancing efficiencies in clinical trials and research
- Reducing single-use products and unnecessary plastics and medical/hazardous waste throughout research and manufacturing
- Creating or promoting alternative packaging that may be reusable, recyclable or biodegradable without compromising sterility or safety
- Optimizing the transportation of supplies and treatments by addressing shipping inefficiencies, cold storage and last-mile delivery
Learn more and submit an application here by
“This year’s Horizon Prize challenges innovators to bring forward ideas that can decrease research inefficiencies while also addressing issues that rare disease patients and their caregivers face,” said
The 2022 Horizon Prize focused on improving quality of life for those diagnosed with rare diseases. The winner,
“The funding we received from the Horizon Prize in 2022 provided us with a great foundation to further advance a centralized platform for patients with EB and their caregivers,” said
About Horizon
Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.
References
-
Uegaki, K., & Billiones, R. (2022). Preventing Biomedical Research Waste.
European Medical Writers Association , 31(1), 20–25.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230418005327/en/
Media:
Executive Director, Corporate Visibility and Media Strategy
media@horizontherapeutics.com
Associate Director, Corporate Communications
media@horizontherapeutics.com
Source: